Perindopril - Therapeutic use
Research News and Information

Monday, November 23, 2009

Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial).

20 Sep 2009 OBJECTIVES: The aim of this study was to evaluate the effect of baseline heart rate on the efficacy of atenolol-based compared with amlodipine-based therapy in patients with hypertension uncomplicated by coronary heart disease in the ASCOT-BPLA ... Read more...

Coronary calcium significantly affects quantitative analysis of coronary ultrasound: importance for atherosclerosis progression/regression studies.

30 Aug 2009 BACKGROUND: Coronary atherosclerosis is a dynamic process, which progresses differently in coronary segments containing noncalcified or calcified plaques. This may have implications for the study of the effects of therapy on progression/regression. ... Read more...

Understanding heart failure with preserved ejection fraction: clinical importance and future outlook.

29 Jun 2009 Heart failure (HF) with preserved ejection fraction (HF-PEF) accounts for approximately one half of all HF patients admitted with acute decompensated HF and carries a significant morbidity and mortality burden. This condition, however, has been ... Read more...

Latest indexed articles for 'Perindopril - Therapeutic use'

These are the very latest articles for this heading:

• Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial). 20 Sep 2009
• Coronary calcium significantly affects quantitative analysis of coronary ultrasound: importance for atherosclerosis progression/regression studies. 30 Aug 2009
• Understanding heart failure with preserved ejection fraction: clinical importance and future outlook. 29 Jun 2009
• Effects of ARB or ACE-inhibitor administration on plasma levels of aldosterone and adiponectin in hypertension. 29 Jun 2009
• The effects of perindopril on aortic elasticity and inflammatory markers in hypertensive patients. 29 Jun 2009
• Perindopril decreases P wave dispersion in patients with stage 1 hypertension. 30 May 2009
• Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE. 29 Apr 2009
• Consistency of treatment effect of perindopril and indapamide across broad spectrum of vascular disease. 29 Apr 2009
• Heart protection: a key target in the management of patients with diabetes. 29 Apr 2009
• Protection of patients with diabetes, with or without hypertension: implications of ADVANCE for clinical practice. 29 Apr 2009
• Effects of perindopril on cardiac remodelling and prognostic value of pre-discharge quantitative echocardiographic parameters in elderly patients after acute myocardial infarction: the PREAMI echo sub-study. 28 Apr 2009
• Long term monitoring in patients receiving treatment to lower blood pressure: analysis of data from placebo controlled randomised controlled trial. 28 Apr 2009
• Severe cerebral white matter hyperintensities predict severe cognitive decline in patients with cerebrovascular disease history. 21 Apr 2009
• A case of Parkinson's disease worsened by captopril: an unexpected adverse effect. 13 Apr 2009
• Effects of the end point adjudication process on the results of the Perindopril Protection Against Recurrent Stroke Study (PROGRESS). 7 Apr 2009
• The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. 2 Apr 2009
• [Hypotensive and metabolic effect of indapamide and perindopril in patients with type 2 diabetes and arterial hypertensia] 30 Mar 2009
• [Fixed combination perindopril-amlodipine (Coveram) in the treatment of hypertension and coronary heart disease] 30 Mar 2009
• ACE-inhibitor suppresses the apoptosis induced by endoplasmic reticulum stress in renal tubular in experimental diabetic rats. 17 Mar 2009
• Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. 9 Mar 2009

See a longer list of these articles.

Technical information about 'Perindopril'

Definition: An angiotensin-converting enzyme inhibitor. It is used in patients with hypertension and heart failure.

Chemical name: 1H-Indole-2-carboxylic acid, 1-(2-((1-(ethoxycarbonyl)butyl)amino)-1-oxopropyl)octahydro-

Registry Number: 82834-16-0

Descriptor UI: D020913

Alternative terms: Perindopril; Pirindopril; Perstarium; S-9490; S 9490; S9490; S 9490-3; S 9490 3; S 94903; Perindopril Erbumine; Erbumine, Perindopril;

Allowable Qualifiers: administration & dosage; adverse effects; analogs & derivatives; analysis; antagonists & inhibitors; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Pharmacological Action: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents;

Tree Number: D03.438.473.766;

History Note: 2000; use PERINDOPRIL (NM) 1985-1999